NC // Decision Intelligence powered by Claim Forensics

Know when the record to challenge a claim is still moving.

Evidence often stabilizes before institutions formally act. We identify the evidence patterns that materially change the read—so you can decide while the window is still open. Identify generic entry signals 90+ days early.

For P&T committees, payer policy reviews, and coverage decisions: know when a disputed claim has stabilized—and whether it is still safe to challenge. Delivered as a 1-page decision brief.

One Claim To Challenge
One Decision P&T / Policy
Window Status Open / Closing

01 // THE PROBLEM

Evidence stabilizes before you vote.

By the time a P&T committee meets or a payer policy locks, the evidence may already be too settled to challenge. We identify these stability signals before the decision window narrows.

We show what holds, what is contested, and what evidence shifts would change the call.

When this matters:

  • Payer re-engagement timing
  • P&T committee docket reviews
  • Formulary exclusion challenges
  • Coverage policy reconsiderations
  • Generic entry defense strategy
  • Guideline adoption deadlines

02 // THE OUTPUT

A challenge brief your team can forward to the committee.

Each brief answers: Can this claim still be challenged, and how much time do we have?

Window status (Open / Narrowing / Closing), what holds, what is under stress, what would reverse the read, and a suggested action envelope for your challenge strategy.

1-Page Decision Brief For P&T / Policy Review
  • Window Status: Open / Narrowing / Closing
  • What Changed: Trajectory of evidence shifts
  • What Holds: Stable evidence supporting the read
  • What Is Under Stress: Contested evidence points
  • What Would Reverse: Reversal conditions
Trust Boundary

We measure the decision window. We do not predict P&T votes or guarantee challenge success.

Start

Have a claim you need to challenge before a decision locks?

Send the claim, the decision date, and what is at stake. We respond within one business day with fit, limits, and whether the window to challenge is still open.

Requests require a verified institutional email address and are subject to current measurement scope.

Today's Read finerenone-cardiorenal
Hardening
Signal 0.38 / Gate 0.65
Phase 1b pending review. Other lanes: dossier-build.

Visual Debug

Page:

Width: px

Theme: